StockData
AbbVie Inc. logo

AbbVie Inc.

ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026Score 10/3089% above fair value
$288.84−6.05 (-2.05%)

Close on Nov 2, 2026Market cap $510.41BP/E 81.6Yield 2.30%

AbbVie Janssen Biotech Collaboration (Imbruvica) by Year

Janssen Biotech Collaboration (Imbruvica) — International Profit Share in Net Revenues ($M) ($M)

QuarterlyAnnual

AbbVie Janssen Biotech Collaboration (Imbruvica): $821M in FY2025, down 8.7% from a year earlier.

Latest, FY2025
821
Period ended Dec 31, 2025
Change on a year earlier
-8.7%
899 in FY2024
History
8 years
Since FY2018
Sources
6
Documents cited below

Where the FY2025 figure comes from

Source: Form 10-K (filed 2026-02-20) ↗

Reported in Form 10-Q / 10-K Licensing, Acquisitions & Other Arrangements Note.

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedJanssen Biotech Collaboration (Imbruvica) — International Profit Share in Net Revenues ($M) ($M)Year on yearSource
FY2025Dec 31, 2025821-8.7%Form 10-K (filed 2026-02-20) ↗
FY2024Dec 31, 2024899-3.4%Form 10-K (filed 2026-02-20) ↗
FY2023Dec 31, 2023931-18.5%Form 10-K (filed 2026-02-20) ↗
FY2022Dec 31, 20221,142+5.1%Form 10-K (filed 2025-02-14) ↗
FY2021Dec 31, 20211,087+7.7%Form 10-K (filed 2024-02-20) ↗
FY2020Dec 31, 20201,009+19.5%Form 10-K (filed 2023-02-17) ↗
FY2019Dec 31, 2019844+35.7%Form 10-K (filed 2022-02-18) ↗
FY2018Dec 31, 2018622–Form 10-K (filed 2021-02-19) ↗

Breakdown

What makes up janssen Biotech Collaboration (Imbruvica)

Cite this data

StockData. (2026). AbbVie Janssen Biotech Collaboration (Imbruvica) ($M), annual FY2018–FY2025 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/collab-janssen-rev

See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.